Vanda Pharmaceuticals | VNDA - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
Akebia Therapeutics 362.52M 357.69M 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Anika Therapeutics 179.39M 556.84M 2026-03
Arrowhead Research USD 22.5M 811K 2025-12
AstraZeneca USD 484M 181M 2025-12
Bristol-Myers Squibb USD 411M 21M 2026-03
Eli Lilly USD 114.7M 134.3M 2025-09
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Esperion Therapeutics USD 22.64M 585K 2025-12
Halozyme Therapeutics USD 5.51M 597K 2026-03
Heron Therapeutics USD 600K 100K 2024-12
Insmed USD 20.08M 517K 2026-03
J&J USD 43M 25M 2026-03
Lexicon Pharmaceuticals USD 2.03M 124K 2025-12
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
Merck USD 479M 67M 2026-03
Minerva Neurosciences USD 2.31M 60K 2024-06
Moderna USD 11.49B 36B 2026-03
Novartis USD 281M 8M 2025-09
Pfizer USD 671M 40M 2026-03
PTC Therapeutics USD 2.87B 2.82B 2026-03
Puma Biotechnology USD 3.37M 11K 2024-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 178M 203M 2026-03
Takeda JPY 43.65B 79.98B 2026-03
Teva Pharmaceutical Industries USD 216M 4M 2026-03
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
Vanda Pharmaceuticals -1.37B 1.97B 2025-12
Veracyte USD 2K 1000 2023-12